Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan. ...

Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers He... ...

Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an i... ...

Core Insights - Eli Lilly reported Q4 earnings that exceeded analyst expectations, with a profit of $7.54 per share on sales of $19.3 billion, compared to forecasts of $6.93 per share on $17.9 billion in sales [1] - Despite strong earnings, Eli Lilly's stock fell 6% due to competitive pressures from Hims & Hers Health, which announced a new "needle-free" GLP-1 weight loss pill [1][3] Group 1: Eli Lilly's Performance - Eli Lilly's Q4 earnings beat expectations, forecasting full-year 2026 earnings between $33.50 and $35 per share [1] - The company achieved significant sales driven by injectable GLP-1 weight loss drugs Mounjaro and Zepbound in 2025 [2] Group 2: Competitive Landscape - Hims & Hers Health introduced a compounded semaglutide pill priced at $49 for the first month, which is significantly lower than Eli Lilly's Zepbound price of $299 for the lowest-dose formulation [3][4] - Hims & Hers plans to increase the price of its GLP-1 pill to $99 per month after the introductory period, but it remains competitive compared to Novo Nordisk's pricing [4][5] - Novo Nordisk offers its injectable Wegovy at $199 and its pill form at $149, indicating a competitive pricing environment for GLP-1 drugs [4]

The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started. ...

Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. ...

Hims And Hers Will Undercut Wegovy Pill With $49 Copy—Novo Stock Shuddershttps://t.co/lkJhiAtuMC https://t.co/tANMf7dnVM ...

Weight-loss drugmakers Eli Lilly and Novo Nordisk fell after telehealth company Hims & Hers announced Thursday it will offer a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.Copenhagen-listed shares of Novo dropped 7% on the news, while Eli Lilly stock fell 6.1% shortly after the opening bell.Hims & Hers stock soared 10%.Novo launched the Wegovy pill in the U.S. early January and CEO Mike Doustdar told CNBC on Wednesday that 170,000 people were already ...

"我们很高兴找到方法，继续通过平台跨专科推出品牌治疗方案。对客户而言，平台上有更多选择是最 好的事情，"Hims首席执行官Andrew Dudum在一份声明中说。 周四，Hims&Hers Health(HIMS.US)盘前大涨近14%，报27.77美元。消息面上，据报道，该公司以每月 49美元的优惠价开始提供新推出的Wegovy药片的仿制版，较品牌药物便宜约100美元。Hims表示，该疗 法可以针对希望避免副作用或更喜欢药片而非注射选项的患者进行定制。 ...

"我们很高兴找到方法，继续通过平台跨专科推出品牌治疗方案。对客户而言，平台上有更多选择是最 好的事情，"Hims首席执行官Andrew Dudum在一份声明中说。 智通财经APP获悉，周四，Hims & Hers Health(HIMS.US)盘前大涨近14%，报27.77美元。消息面上，据 报道，该公司以每月49美元的优惠价开始提供新推出的Wegovy药片的仿制版，较品牌药物便宜约100美 元。Hims表示，该疗法可以针对希望避免副作用或更喜欢药片而非注射选项的患者进行定制。 ...